



Session V

Clinical Evaluation and Management of Internal Contamination

Objectives

- Discuss the diagnosis of internal contamination.
- Describe the health effects of internal contamination.
- Discuss the management principles of internal contamination.
- Describe the use of principle therapies in internal contamination.






Nasal Swabs

- A swab is collected from each nostril of individuals who have potentially inhaled radionuclides in the form of particulate matter.
- Each swab gets tested for the detection of radiation.
- The radiation present in the nasal cavities will reflect the presence of radionuclides in lower air spaces and subsequent internal contamination.

80



Diagnosis By Excretion (Bioassay) Sampling

Collect urine or feces to measure excretion rates.Challenging interpretation

- Time when contaminationoccured

- Charcteristics of inhaled or internalized radionuclides

Management Strategies

Supportive care.


EMORY

- Decreasing absorption.
- Decorporation and enhanced elimination.
- Long term monitoring.

REAC/TS Should be Contacted for Assistance

Radionuclide	Medication
lodine	KI (potassium iodide)
Transuranics such as Plutonium & Americium	Zn-DTPA Ca-DTPA
Uranium	Bicarbonate
Cesium Rubidium Thallium	Prussian Blue* [Ferrihexacyano- Ferrate (II)]
Tritium	Water





EMORY HEDOCOM

Retention (% of Uptake)	Control	Treated with DTPA
Liver	14.0	0.47
Skeleton	57.0	5.9

	Radioactivity as Percent of Control	
Time to treatment	Liver	Skeletor
1, 24, 48 nours	7	10
′ - 11 lays	22	46






Table 2: Cesium-137 Effective Half-life During and After Treatment with Insoluble Prussian blue (In Davs, by Age, and Dose of Insoluble Prussian blue)					
Group	Age (Years)	Insoluble Prussian blue dose (grams/day)	No. of Pts.	During Insoluble Prussian blue Treatment - ¹³⁷ Cs T ₁₂	Off Insoluble Prussian blue Treatment - ¹³⁷ Cs T ₁₂
Adults	> 18	10	5	26 ± 6 days	80 ± 15 days (all
Adults	> 18	6	10	25 ± 15 days	21 adult patients)
Adults	> 18	3	6	25 ± 9 days	
Adolescents	12 -14	< 10	5	30 ± 12 days	62 ± 14 days
Children	4 - 9	< 3	7	24 ± 3 days	42 ± 4 days
PB treatm		e decreased		en 43 & 60% /37Cs ratio for	1:4 to 4:1


_


_

_

_














Dose depends on age, special considerations (pregnant, lactating), and dose to thyroid gland.

Age Calegory	Predicted Absorbed Dose to the Thyroid Gy (rad) ^{to}	KI Dum (mg?	Number of 130 mg Tableta	Number of 65 mg Tablota	KI Solution 65 mg mL (mL)
Adults >40 y	25 (500)	130	1	2	
Adults 18-40 y	20.1 (10)	130	1	2	
Prognant or lactating women	20.05 (5)	130	1	2	
Adolescents 12 - 18 ye	20.05(5)	65	0.5	1	1
Children 3 – 12 y	20.05(5)	65	0.5	1	1
1 month - 3 y	20.05 (5)	712	0.25	0.5	0.5
Birth - 1 month	20.05 (5)	16	0.125	0.25	0.25
exposure to radioisdines by eith Without KI treatment.	aste -24 h. For optimal proph ser inhalation or ingestion no b dt size (>70 kg) should receive	onger exists.		torod daily, ustil a	riak of eignife



If Exposure to 131-I Longer than 1 Day

- Additional protective actions should be prioritized for children and pregnant or lactating women.
- Repeat doses of KI may have to be given up to 10-14 days.
 - May need to check thyroid hormone levels in certain high risk populations.

<section-header><section-header><image><image>

Psychological Issues Following Radiation Disasters


 Unique because of the public's intense fear of radiation, strong sense of fatalism, and social stigma attached to persons exposed or contaminated.



50







Psychological Issues Following Radiation Disasters

 The largest impact of a radiation disaster may be psychosocial.




 Psychological first aid assists survivors to keep risks in perspective.

EMOR



8





- Internal contamination with radionuclides can lead to acute and long term health effects.
- Removing the radionuclide or decreasing absorption are the mainstays of therapy.
- The specific therapy depends on the radionuclide in question.

